Literature DB >> 23957517

Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.

Guogen Shan1, Changxing Ma, Alan D Hutson, Gregory E Wilding.   

Abstract

In areas such as oncology, two-stage designs are often preferred as compared to one-stage designs due to the ability to stop the trial early when faced with evidence of lack of sufficient efficacy and the associated sample size savings. We present exact two-stage designs based on Barnard's exact test for differences in proportions and compare the designs to those proposed by Kepner ( 2010 ) and Jung ( 2010 ). In addition, we present tables of decision rules under a variety of assumed realities for use in trial planning. The procedure is recommended for use due to the substantial sample size savings experienced.

Mesh:

Year:  2013        PMID: 23957517     DOI: 10.1080/10543406.2013.813525

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  13 in total

1.  Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints.

Authors:  Guogen Shan
Journal:  J Biopharm Stat       Date:  2020-03-04       Impact factor: 1.051

2.  Optimal inference for Simon's two-stage design with over or under enrollment at the second stage.

Authors:  Guogen Shan; John J Chen
Journal:  Commun Stat Simul Comput       Date:  2017-06-20       Impact factor: 1.118

3.  Randomized two-stage optimal design for interval-censored data.

Authors:  Guogen Shan
Journal:  J Biopharm Stat       Date:  2021-12-10       Impact factor: 1.503

4.  Optimal adaptive two-stage designs for early phase II clinical trials.

Authors:  Guogen Shan; Gregory E Wilding; Alan D Hutson; Shawn Gerstenberger
Journal:  Stat Med       Date:  2015-11-03       Impact factor: 2.373

5.  Efficient confidence limits for adaptive one-arm two-stage clinical trials with binary endpoints.

Authors:  Guogen Shan; Hua Zhang; Tao Jiang
Journal:  BMC Med Res Methodol       Date:  2017-02-06       Impact factor: 4.615

6.  Cannabinoid antagonist SLV326 induces convulsive seizures and changes in the interictal EEG in rats.

Authors:  Martin F J Perescis; Natasja de Bruin; Liesbeth Heijink; Chris Kruse; Lyudmila Vinogradova; Annika Lüttjohann; Gilles van Luijtelaar; Clementina M van Rijn
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

7.  Statistical advances in clinical trials and clinical research.

Authors:  Guogen Shan; Sarah Banks; Justin B Miller; Aaron Ritter; Charles Bernick; Joseph Lombardo; Jeffrey L Cummings
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-14

8.  Accurate confidence intervals for risk difference in meta-analysis with rare events.

Authors:  Tao Jiang; Baixin Cao; Guogen Shan
Journal:  BMC Med Res Methodol       Date:  2020-04-30       Impact factor: 4.615

9.  A stochastically curtailed two-arm randomised phase II trial design for binary outcomes.

Authors:  Martin Law; Michael J Grayling; Adrian P Mander
Journal:  Pharm Stat       Date:  2020-08-29       Impact factor: 1.894

10.  Optimal two-stage designs based on restricted mean survival time for a single-arm study.

Authors:  Guogen Shan
Journal:  Contemp Clin Trials Commun       Date:  2021-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.